| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The ability of insulin-like growth factor-I (IGF-I) to protect against losses of body protein during periods of dietary nitrogen restriction has been evaluated in young rats. Recombinant human IGF-I was administered by osmotic pumps at dose rates of 0, 1·2 or 2·9 mg/kg per day over a 7-day period beginning with the transfer of animals from an 18% to a 4% protein diet. A fourth group received the potent truncated IGF-I analogue, des(1–3)IGF-I, at a dose of 1·2 mg/kg per day over a comparable 7-day period. Plasma IGF-I levels were reduced by 60% following nitrogen restriction, a reduction that was partly prevented by IGF-I administration, especially at the higher dose, but not measurably by des(1–3)IGF-I. The major IGF-binding protein circulating in blood, IGFBP-3, demonstrated a similar pattern of change.
A significant (P<0·05) protection of body weight was achieved in the low dose IGF-I and des(1–3)IGF-I groups, but only after differences in food intake had been eliminated by analysis of covariance. Nitrogen balances were not significantly different unless analysis of covariance was used to adjust for the nitrogen intakes, whereupon all treatment groups showed improved balance, especially the animals treated with the low IGF-I dose and des(1–3)IGF-I (both P<0·01). The rate of muscle protein breakdown calculated from the urinary excretion of 3-methylhistidine was not significantly altered by the treatments, but fell progressively throughout the 7 days. The fractional rate of muscle protein synthesis measured on the final day was increased by 31, 26 and 21% respectively by the low and high doses of IGF-I and by des(1–3)IGF-I. Organ weights (g/kg body weight) showed no effects of IGF-I treatment except for 16% increases in the weight of kidneys in the high dose IGF-I and the des(1–3)IGF-I groups. Carcass analyses demonstrated higher water and lower fat contents (all P< 0·01) in the same groups. These results suggest that exogenous IGF-I and especially des(1–3)IGF-I can partly protect body protein reserves during nitrogen restriction.
Journal of Endocrinology (1991) 128, 97–105
This article has been cited by other articles:
|
|
 |
|
  J. L. Bailey, B. Zheng, Z. Hu, S. R. Price, and W. E. Mitch Chronic Kidney Disease Causes Defects in Signaling through the Insulin Receptor Substrate/Phosphatidylinositol 3-Kinase/Akt Pathway: Implications for Muscle Atrophy J. Am. Soc. Nephrol., May 1, 2006; 17(5): 1388 - 1394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Samani, E. Chevet, L. Fallavollita, J. Galipeau, and P. Brodt Loss of Tumorigenicity and Metastatic Potential in Carcinoma Cells Expressing the Extracellular Domain of the Type 1 Insulin-Like Growth Factor Receptor Cancer Res., May 15, 2004; 64(10): 3380 - 3385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mero, J. Kahkonen, T. Nykanen, T. Parviainen, I. Jokinen, T. Takala, T. Nikula, S. Rasi, and J. Leppaluoto IGF-I, IgA, and IgG responses to bovine colostrum supplementation during training J Appl Physiol, August 1, 2002; 93(2): 732 - 739. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Kee, R. C. Baxter, A. R. Carlsson, and R. C. Smith Parenteral amino acid intake alters the anabolic actions of insulin-like growth factor I in rats Am J Physiol Endocrinol Metab, July 1, 1999; 277(1): E63 - E72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. Hill and J. M. Pell Regulation of Insulin-Like Growth Factor I (IGF-I) Bioactivity in Vivo: Further Characterization of an IGF-I-Enhancing Antibody Endocrinology, March 1, 1998; 139(3): 1278 - 1287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Mero, H. Miikkulainen, J. Riski, R. Pakkanen, J. Aalto, and T. Takala Effects of bovine colostrum supplementation on serum IGF-I, IgG, hormone, and saliva IgA during training J Appl Physiol, October 1, 1997; 83(4): 1144 - 1151. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
